Navigation Links
Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
Date:3/4/2013

requent adverse events (AEs) in STARTVerso™ 4 were nausea (37%), fatigue (33%), diarrhea (27%), headache (23%), and weakness (22%). Serious AEs were reported in 32 patients (10%), including three deaths. To date, 18 patients have discontinued study participation due to AEs. The safety results of this study were comparable to those observed in HCV mono-infected treatment-naive patients in prior faldaprevir clinical studies. No patient on ART experienced a loss of HIV viral suppression during the study period.

In a separate oral presentation at CROI, investigators described the results from three open-label Phase 1 studies in healthy volunteers that evaluated the drug-drug interactions of faldaprevir with the common HIV medications darunavir/ritonavir, efavirenz, or tenofovir. In each of these studies, there was no clinically relevant effect of faldaprevir on the pharmacokinetics of any of the HIV medications studied. However, the respective effects of darunavir/ritonavir and efavirenz on faldaprevir informed the study design of STARTVerso™ 4. Patients already taking darunavir/ritonavir or efavirenz were enrolled into the 120mg and 240mg faldaprevir groups in STARTVerso™ 4, respectively.

These drug-drug interaction findings are part of a comprehensive program to evaluate potential drug interactions of faldaprevir with other medications commonly taken by the diverse patient populations infected with HCV. Most AEs in the drug-drug interaction studies were mild or moderate and all were resolved by the end of the trials. Four healthy volunteers discontinued trial participation due to AEs, including mild or moderate rash, mild elevation in hepatic enzyme levels, or moderate myalgia.

"The interim virologic response rates from STARTVerso™ 4 in HCV/HIV co-infected patients, combined with the drug-drug interaction results of faldaprevir with common HIV medications, are encouraging as we continue toward our goal of developing new HCV
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , August 1, 2014 ... by Type (Traditional Wound Closure, Anti infective), Basic (Films, ... Skin & Skin Substitutes), Pressure Relief Devices, NPWT) ... global Wound Care Market is expected to reach ... 2014, growing at a CAGR of 3.2% from ...
(Date:8/1/2014)... Pa. , Aug. 1, 2014 Inovio ... will host a conference call to report its second ... at 9:00 AM ET. CEO Dr. J. Joseph ... discuss second quarter earnings, provide a corporate update, and ... will include clinical development plans for VGX-3100, Inovio,s immune ...
(Date:7/31/2014)... 2014  According to data released today by the ... monthly Medicare Part D premium is expected to remain ... originally projected, the Pharmaceutical Care Management Association (PCMA) said. ... be a bright spot in American health care. By ... and using cutting edge, cost-saving tools like pharmacy networks ...
Breaking Medicine Technology:Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
(Date:8/2/2014)... KY (PRWEB) August 02, 2014 ... Lakeview Estates neighborhood on Lexington’s southeast side, has undertaken ... a little better in the “green” sense, while improving ... Brad Rose, Lakewood Park’s property manager, announced that Lakewood ... its tenants. “We’re really excited about being able ...
(Date:8/2/2014)... August 02, 2014 CEDR HR ... number one provider of customized medical and dental employee ... dental-industry conferences this fall. CEDR’s CEO will be featured ... and early December. , From September 4-6, CEDR will ... Managers (AADOM) Dental Managers Conference in San Diego, to ...
(Date:8/1/2014)... (PRWEB) August 02, 2014 The successful ... the stamping business of Guangdong FODAY Automobile Co.,LTD. As ... the company had already organized an excellent team to ... number of detailed, in-depth technical plans. The company’s vice ... were in the direct involvement of the specific arrangement ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... appetite and whole-body metabolism. A protein known as PPARγ ... and body weight, but the identity of the neurons ... new study in the Journal of Clinical Investigation ... neuron known as pro-opiomelanocortin (POMC) neurons is critical in ... and colleagues at Yale University School of Medicine found ...
Breaking Medicine News(10 mins):Health News:Lexington’s Lakewood Park Apartments Getting Into Gardening 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 3Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2
... University shows for the first time that the brain ... food and drugs - offering insights into our propensity ... boxing and football. , The research will be published ... Psychopharmacology. , Aggression occurs among virtually all vertebrates and ...
... Routing cue works like a Zip code helps deliver mail, ... researchers have found a way to modify the surface of ... advance that may prove useful in many areas of stem ... at Brigham and Women,s Hospital in Boston modified the surface ...
... $25.5 Million Investment in Detroit - Opens Thursday, DETROIT, ... of Detroit Mercy will be opening a new School of ... giving back to,the City of Detroit. The new wireless facility ... country., Over 261,000 square feet, the School,s new location ...
... Recognising people, objects or animals by the sound they make ... take for granted. But very similar objects can physically make ... subtle clues about the identity and source of the sound. ... (BBSRC) are working out how the human ear and the ...
... into ,skeleton, of animal organ was beating in just ... An organ-building biotechnology that could create transplantable hearts using ... laboratory tests, researchers report. , The technique, called whole ... tissue, according to a report in the Jan. 13 ...
... Fortune 500 Executive Driving Global Breast Cancer Leader,s Promise ... Quickly, End Breast Cancer Forever, ATLANTA, Jan. 12 ... Cure, the global leader in the fight to end breast,cancer ... the,16th annual Trumpet Awards event in Atlanta with a ,High ...
Cached Medicine News:Health News:Aggression as rewarding as sex, food and drugs 2Health News:Stem Cells Modified to Home in Where They're Needed 2Health News:University of Detroit Mercy School of Dentistry Moves to Larger Facility on New Corktown Campus 2Health News:University of Detroit Mercy School of Dentistry Moves to Larger Facility on New Corktown Campus 3Health News:Lend me your ears -- and the world will sound very different 2Health News:Biotechnology Builds a New Heart 2Health News:Biotechnology Builds a New Heart 3Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3
Head-worn Loupe G3, Galilean teleloupe system....
... The XL Advantage delivers higher magnification for ... crisp, true image, even at the highest ... edge clarity and precise color rendition is ... with an anti-reflective coating produce a superior ...
... The XL Advantage delivers higher magnification ... a crisp, true image, even at the ... to edge clarity and precise color rendition ... treated with an anti-reflective coating produce a ...
... higher magnification for advanced surgical procedures. Prismatic ... at the highest magnification. 3.5x, 4.5x and ... color rendition is ideal for surgical applications. ... produce a superior image. The compact abd ...
Medicine Products: